Our night formule with a clever combination of liposomal CBD and Melatonin
Health benefits liposomal CBD & Melatonin
Our liposomal supplement that addresses anxiety and sleep quality features a clever combination of CBD and Melatonin which ensures maximal absorption of CBD as a result of our proprietary formulation process and liposome technology.
What is CBD?
Cannabidiol (CBD) is one of the several natural active ingredients of the Cannabis plant. It differs from tetrahydrocannabinol (THC) in that it lacks the well-known psychoactive effects . Instead, it has a range of beneficial effects, most notably at the level of anxiety [1-3] and sleep [4,5], but also on inflammation [1,3], cognition, movement disorders, and peripheral pain . It is currently applied as a drug treatment for some forms of epilepsy (Dravet and Lennox-Gastaut syndrome) [7,8].
Why is Melatonin added?
Melatonin is a naturally produced hormone that regulates the sleep-wake cycle. Supplementation of melatonin safely and effectively improves sleep initiation, duration and quality. In addition, melatonin therapy can help stabilize the sleep-wake rhythm in people who are unable to synchronize their cycle with the environmental day-night cycle (due to jet lag or shift work for example) [9,10]. It has also been beneficial in the treatment of other diseases including liver diseases , eczema  and bipolar disorders .
Limitations of current CBD and Melatonin products
CBD is completely insoluble in water, poorly dissolves in alcohol and only dissolves well in oil. Indeed, most products on the market are oil solutions of CBD. While this seems a logic choice, as a matter of fact the use of oils for formulating CBD supplements is far from ideal. To be optimally absorbed in the intestines, CBD must be presented as individual molecules to the intestinal epithelial cells responsible for uptake of nutrients. In theory products with oily solutions could achieve this, but in practice the break up of an oil by the intestinal fluid and the process of dispersing it into tiny droplets ready for absorption is not straightforward and there are reports of poor bioavailability and high variability in uptake of CBD from oil products . Although melatonin is more soluble  the bioavailability of oral melatonin is still relatively low. This is due to high first-pass clearance in the liver and low absorption in the gastrointestinal tract [16,17]. Thus, there is a clear need for a product that leads to improved absorption of both actives combined.
Our liposomal CBD & Melatonin supplement is a superior version of a CBD and melatonin combination supplement. Liposomes are small, carefully designed phospholipid vesicles that form very stable dispersions in water . The phospholipids constitute a bilayer structure in which the CBD and melatonin molecules can be safely kept dissolved, protecting them from degradative enzymes . In addition, liposomes are more easily absorbed by intestinal epithelial cells compared to non-carrier formulations [20,21].
What is more, the liposomal supplements that are engineered by LIPOSOMA contain specific additives based on Vitamin E in the bilayer that further increase liposome stability and help protect its vulnerable contents against oxidation as well as attack of gastric fluids and enzymes. This ensures maximal efficiency in body uptake and therapeutic benefit.
To conclude, with this supplement we provide you a highly bioavailable and effective combination of CBD and melatonin that helps you fall asleep and maintain a healthy sleep rhythm whilst benefiting from the numerous other effects that are being studied and documented about these natural substances.
“Our liposomal vitamins and other nutraceuticals are available as raw materials, capsules, liquids and many other tailored solutions. “
LIPOSOMA Nutraceuticals; experts in liposomes
LIPOSOMA manufactures branded and white label liposomal supplements.
Our high-end liposomal nutraceuticals are guaranteed by the academic qualifications of our team and its commitment to scientific excellence.
Our liposome technology offers many advantages for nutritional supplement producers, the food sector and consumers. Our liposomal vitamins and other nutraceuticals are available as raw materials, capsules, liquids and many other tailored solutions.
Would you like to learn more? Give us a call at 0031 20 237 36 00
 Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V., & Mechoulam, R. (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in pharmacological sciences, 30(10), 515-527.
 Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836.
 Mechoulam, R., Parker, L. A., & Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. The Journal of Clinical Pharmacology, 42(S1), 11S-19S.
 Babson, K.A., Sottile, J., Morabito, D. (2017). Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Current Psychiatry Reports 19(4), 23.
 Shannon, S., Lewis, N., Lee, H., Hughes, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente Journal 23, 18-041.
 Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., et al. (2018). The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology, 43(1), 52.
 Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., et al. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine, 376(21), 2011-2020.
 Devinsky, O., Patel, A. D., Thiele, E. A., Wong, M. H., Appleton, R., Harden, C. L., .et al. (2018). Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology, 90(14), e1204-e1211.
 Xie, Z., Chen, F., Li, W.A., Geng, X., Li, C., Meng, X., Feng, Y., Liu, W., Yu, F. (2017). A review of sleep disorders and melatonin. Neurological Research 6, 559-565. doi: 10.1080/01616412.2017.1315864.
 Zisapel, N. (2018). New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. British Journal of Pharmacology 175(16), 3190-3199. doi: 10.1111/bph.14116. Epub 2018 Jan 15.
 Bonomini F, Borsani E, Favero G, Rodella LF, Rezzani R. (2018). Dietary Melatonin Supplementation Could Be a Promising Preventing/Therapeutic Approach for a Variety of Liver Diseases. Nutrients. 2018 Aug 21;10(9). pii: E1135.
 Taghavi Ardakani, A., Farrehi, M., Sharif, M.R., Ostadmohammadi, V., Mirhosseini, N., Kheirkhah, D., Moosavi, S.G.A., Behnejad, M., Reiter, R.J., Asemi, Z. (2018). The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double-blinded, placebo-controlled trial. Pediatric Allergy and Immunology 29(8), 834-840. doi: 10.1111/pai.12978.
 Geoffroy, P.A., Etain, B., Franchi, J.A., Bellivier, F., Ritter, P. (2015). Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders. Current Pharmaceutical Design 21(23), 3352-8.
 Zgair, A., Wong, J. C., Lee, J. B., Mistry, J., Sivak, O., et al. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research, 8(8), 3448.
 Shida, C.S., Castrucci, A.M., Lamy-Freund, M.T. (1994). High melatonin solubility in aqueous medium. Journal of Pineal Research 16(4), 198-201.
 Harpsøe, N.G., Andersen, L.P., Gögenur, I., Rosenberg, J. (2015). Clinical pharmacokinetics of melatonin: a systematic review. European Journal of Clinical Pharmacology 71(8), 901-9. doi: 10.1007/s00228-015-1873-4.
 Tordjman, S., Chokron, S., Delorme, R., Charrier, A., Bellissant, E., Jaafari, N., Fougerou, C. (2017). Melatonin: Pharmacology, Functions and Therapeutic Benefits. Current Neuropharmacology 15(3), 434-443.
 Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., et al. (2013). Liposome: classification, preparation, and applications. Nanoscale research letters, 8(1), 102.
 Bozzuto, G., Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine 10, 975-99.
 Hafner, A., Lovrić, J., Voinovich, D., Filipović-Grcić, J. (2009). Melatonin-loaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers. International Journal of Pharmaceutics 381(2), 205-13. doi: 10.1016/j.ijpharm.2009.07.001.
 Liu W, Ye A, Han F, Han J. (2019). Advances and challenges in liposome digestion: Surface interaction, biological fate, and GIT modeling. Advances in Colloid and Interface Science 263, 52-67. doi: 10.1016/j.cis.2018.11.007.
Andersen, L. P., Werner, M. U., Rosenkilde, M. M., Harpsøe, N. G., Fuglsang, H., Rosenberg, J., & Gögenur, I. (2016). Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC pharmacology & toxicology 17, 8. doi: 10.1186/s40360-016-0052-2.